Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 14,800 shares, an increase of 5.7% from the October 31st total of 14,000 shares. Based on an average trading volume of 3,100 shares, the short-interest ratio is currently 4.8 days.
Intellipharmaceutics International Stock Performance
IPCIF opened at $0.08 on Friday. Intellipharmaceutics International has a 1-year low of $0.07 and a 1-year high of $0.30. The stock's fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.09.
Get Intellipharmaceutics International alerts:About Intellipharmaceutics International
(Get Rating)
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.Further Reading
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.